Tolerability of the intravenous immunoglobulin Octagam® 10%

Trial Profile

Tolerability of the intravenous immunoglobulin Octagam® 10%

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions
  • Sponsors Octapharma
  • Most Recent Events

    • 05 Nov 2016 New trial record
    • 01 Nov 2016 Results assessing safety and tolerability using data from this and other three trials published in the International Journal of Clinical Pharmacology and Therapeutics.
    • 10 Oct 2016 Results assessing safety and tolerability using data from this and other three trials published in the International Journal of Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top